Capital Fund Management S.A. decreased its stake in shares of Intrexon Corporation (NYSE:XON) by 85.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 19,039 shares of the biotechnology company’s stock after selling 108,759 shares during the quarter. Capital Fund Management S.A.’s holdings in Intrexon Corporation were worth $459,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the stock. Alliancebernstein L.P. lifted its position in Intrexon Corporation by 0.6% during the second quarter. Alliancebernstein L.P. now owns 32,610 shares of the biotechnology company’s stock worth $786,000 after buying an additional 200 shares in the last quarter. Private Advisor Group LLC lifted its position in Intrexon Corporation by 9.9% during the second quarter. Private Advisor Group LLC now owns 39,026 shares of the biotechnology company’s stock worth $917,000 after buying an additional 3,524 shares in the last quarter. Leisure Capital Management purchased a new position in Intrexon Corporation during the second quarter worth approximately $231,000. Synovus Financial Corp lifted its position in Intrexon Corporation by 0.6% during the second quarter. Synovus Financial Corp now owns 33,613 shares of the biotechnology company’s stock worth $810,000 after buying an additional 200 shares in the last quarter. Finally, Capital Advisors Inc. OK lifted its position in Intrexon Corporation by 1.6% during the second quarter. Capital Advisors Inc. OK now owns 163,676 shares of the biotechnology company’s stock worth $3,943,000 after buying an additional 2,573 shares in the last quarter. Hedge funds and other institutional investors own 82.11% of the company’s stock.

A number of equities analysts recently commented on XON shares. Northland Securities set a $30.00 price objective on Intrexon Corporation and gave the stock a “buy” rating in a research report on Monday, August 7th. BidaskClub upgraded Intrexon Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Finally, Zacks Investment Research downgraded Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $37.60.

Shares of Intrexon Corporation (NYSE XON) opened at 19.37 on Monday. The firm has a 50-day moving average price of $19.56 and a 200-day moving average price of $21.42. Intrexon Corporation has a 52-week low of $17.03 and a 52-week high of $32.90. The stock’s market cap is $2.33 billion.

Intrexon Corporation (NYSE:XON) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. The firm had revenue of $54.40 million for the quarter, compared to analysts’ expectations of $57.17 million. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. Intrexon Corporation’s quarterly revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.42) EPS. On average, analysts anticipate that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.

In other Intrexon Corporation news, COO Andrew J. Last acquired 2,000 shares of the firm’s stock in a transaction dated Monday, August 14th. The shares were acquired at an average price of $19.99 per share, for a total transaction of $39,980.00. Following the completion of the acquisition, the chief operating officer now directly owns 2,000 shares of the company’s stock, valued at $39,980. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Dean J. Mitchell acquired 5,000 shares of the firm’s stock in a transaction dated Friday, August 11th. The shares were acquired at an average price of $18.33 per share, for a total transaction of $91,650.00. Following the acquisition, the director now directly owns 18,103 shares of the company’s stock, valued at $331,827.99. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 144,569 shares of company stock worth $2,719,429. 56.30% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “Capital Fund Management S.A. Has $459,000 Position in Intrexon Corporation (XON)” was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/09/18/capital-fund-management-s-a-has-459000-position-in-intrexon-corporation-xon.html.

Intrexon Corporation Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corporation (NYSE:XON).

Institutional Ownership by Quarter for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.